China NMPA approves Harbour BioMeds IND application to begin phase 1 trial of B7H4x4-1BB bispecific antibody
Harbour BioMed, a global biopharmaceutical company, announced that China National Medical Products Administration (NMPA) had approved the investigational new drug (IND) application to commence phase I trial of its B7H4x4-1BB bispecific antibody (HBM7008) in China. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumour activity of HBM7008 in patients with solid tumours. It has successfully completed the dosing of first patient in the phase I trial of HBM7008 in Australia on 25 May 2022.
HBM7008 is generated from HBM
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!